e-Therapeutics Plc (ETX.L) posted loss attributable to equity holders of the company of 3.24 million pounds for the year ended January 31, 2012 compared to the loss of 2.31 million pounds last year. Meanwhile, loss per share narrowed to 2.47 pence from 3.51 pence in the prior year.
Pre-tax loss widened to 3.86 million pounds from 2.66 million pounds in the previous year.
The company did not record any revenues for the year.
e-Therapeutics' CFO, Dr Daniel Elger, said, "Our 2012 results reflect increasing investment in drug discovery and drug development made possible by shareholders' support of a significant capital raise during the year. We are confident that continuing this investment will yield promising new drugs and advance our pipeline towards value-realising partnering deals."
Click here to receive FREE breaking news email alerts for e-Therapeutics plc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org